{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:02:00Z","timestamp":1789628520063,"version":"build-2803163510"},"reference-count":16,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2026.2973","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:05:41Z","timestamp":1788422741000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Cumulative cytotoxic chemotherapy exposure after the introduction of PARP inhibitors in advanced high-grade serous tubo\u2011ovarian and primary peritoneal carcinoma: A descriptive single\u2011center historical cohort study"],"prefix":"10.3892","volume":"25","author":[{"given":"Natsuki","family":"Osawa","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenro","family":"Chikazawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kuwata","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"key20260917090410_b1-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20260917090410_b2-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"key20260917090410_b3-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"key":"key20260917090410_b4-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"key20260917090410_b5-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): A randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20260917090410_b6-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): A placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20260917090410_b7-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(24)00674-0","article-title":"Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial","volume":"26","author":"Oza","year":"2025","journal-title":"Lancet Oncol"},{"key":"key20260917090410_b8-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.24.00933","article-title":"Olaparib as treatment versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer: Phase III SOLO3 study final overall survival results","volume":"43","author":"Scambia","year":"2025","journal-title":"J Clin Oncol"},{"key":"key20260917090410_b9-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20260917090410_b10-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","article-title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): A phase IIIb trial","volume":"34","author":"Pujade-Lauraine","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260917090410_b11-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: Post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260917090410_b12-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ygyno.2022.02.002","article-title":"Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1\/2-mutated epithelial ovarian cancer: A multicentre retrospective study","volume":"165","author":"Park","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"e49","key":"key20260917090410_b13-MCO-25-4-02973","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2021.32.e49","article-title":"The 2020 Japan society of gynecologic oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer","volume":"32","author":"Tokunaga","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"key20260917090410_b14-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2025.03.018","article-title":"ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety","volume":"195","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"115584","key":"key20260917090410_b15-MCO-25-4-02973","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115584","article-title":"Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial","volume":"225","author":"Ledermann","year":"2025","journal-title":"Eur J Cancer"},{"key":"key20260917090410_b16-MCO-25-4-02973","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:04:16Z","timestamp":1789625056000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2026.2973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2026.2973","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}